This is a notice of intent to negotiate a sole source fixed-price purchase order with ICAD, Inc. for the renewal and continuation of ICAD 2D/3D detection per exam licenses for their 3D mammography digital breast tomosynthesis suite. The required service provides an AI platform to aid radiologists in mammogram interpretation and includes critical software upgrades. The justification for sole source is ICAD's proprietary technology, the need for continuity of service and patient data, and avoidance of unacceptable risk and cost associated with data migration. This is not a request for quotation, but interested parties who believe they can meet the requirement may submit a capability statement, proposal, or quotation by the response date of April 12, 2026, 1:00 PM MST.
The bid notice does not specify a delivery deadline for the software licenses or services.
The bid notice does not specify the payment terms.
The bid notice does not specify the warranty terms.
The bid notice states that this is a notice of intent to negotiate on a sole source basis, implying the award will be to ICAD, Inc. due to proprietary technology and continuity of service. The bid notice states The bid notice does not specify the award criterion.
The bid notice states that all responsible sources who believe they can meet the requirement as stated herein may submit a capability statement, proposal, or quotation which shall be considered by the agency.
The bid notice does not specify any penalties.
The bid notice does not mention a site visit.
The bid notice does not mention the submission of samples.
The bid notice states that interested parties must identify their interest and capability to respond to this requirement by the response date of April 12, 2026, 1:00 PM MST.
The bid notice does not specify the estimated total value.